Well-established examples include KIT mutations in gastrointestinal stromal tumors (GISTs) that predict response to imatinib or nilotinib, and non-small cell lung cancers with EGFR mutations that are sensitive to erlotinib[1], [2], [3]. Here, KIT is linked to non-small cell lung carcinoma.